Adaptive Biotechnologies Corporation is a biotechnology company that develops clinical diagnostics and therapeutics by sequencing and analyzing the adaptive immune system. The company operates two main business segments: the MRD business, which offers the clonoSEQ test for detecting minimal residual disease in hematologic malignancies such as multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, and the Immune Medicine business, which focuses on T cell receptor and B cell receptor sequencing, antigen mapping, and target discovery for autoimmune diseases like multiple sclerosis and type 1 diabetes. Founded in 2009, the company serves clinicians, biopharmaceutical partners, and research institutions. It maintains partnerships with Pfizer for therapeutic research in rheumatoid arthritis and utilizes its proprietary immunosequencing platform to generate clinical immunomics data. The company’s products are integrated into electronic medical record systems to facilitate test workflow and patient access.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Biotechnology Homepage adaptivebiotech.com
Sector Healthcare IR page investors.adaptivebiotech.com
Tags
immunosequencing, minimal residual disease, hematologic malignancies, autoimmune diseases, t cell receptor sequencing, b cell receptor sequencing, clinical diagnostics, target discovery, antigen mapping, computational biology, clonoSEQ, MRD Pharma, Epic, Flatiron Health, OncoEMR, Pfizer
Press page —

Metrics

Valuation  
Market cap $ 4.674B
Market cap (USD) $ 4.674B
P/E -65.75
PEG —
P/BV 26.53
P/S 15.68
P/OCF —
P/FCF -529.83
Dividend yield —
Turnover / mcap —
Returns  
ROE -28.2%
ROI -17.0%
ROIC -12.2%
Profit margin -21.5%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 60.3%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 49
Quality score -41.2%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 276.976M 178.957M 170.276M 185.308M 154.344M 98.382M 85.071M 55.663M
Net profit -59.499M -159.492M -225.25M -200.191M -207.279M -146.227M -68.606M -46.447M
Free cash flow -48.945M -98.876M -167.021M -200.294M -254.473M -168.486M 194.204M -38.577M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 16.24 6 4.9 7.64 28.06 59.13 29.92 —
Price performance 12m 1.71 0.22 -0.36 -0.73 -0.53 0.98 — —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 4.81M 12.7M 10M 17.4M 40.1M 38M 41.7M 50.4M
↳ YoY growth +163.7% -20.7% +73.3% +130.1% -5.2% +9.9% +20.7%
↳ 5y CAGR +51.2% +26.9% +38.0%
Borrowings, current (USD) — — — — — — — 865,000 4.64M
Borrowings, non-current (USD) — — — — — 125M 131M 132M 127M
Lease liabilities (USD) — — 36.6M 108M 112M 108M 98.8M 89.4M 79.1M
Cash and deposits (USD) — 55M 96.6M 123M 139M 90M 65.1M 47.9M 70.5M
Intangible assets (USD) — 13.6M 11.9M 10.2M 8.53M 6.83M 5.13M 3.43M 1.73M
Right-of-use assets (USD) — — — 99.4M 87.7M 80.8M 52.1M 45.8M 40.6M
Net debt (borrowings + leases - cash) (USD) — — — — — 143M 164M 175M 140M
Cash flow detail
Operating cash flow (USD) -34.9M -32.3M 205M -150M -193M -184M -156M -95.2M -46M
Purchases of property, plant and equipment (USD) -2.42M -6.32M -11.2M -18.8M -61.7M -16.3M -10.7M -3.66M -2.96M
Purchases of intangible assets (USD) -85,000 — — — — — — — —
Change in receivables (cash effect) (USD) -2.43M 775,000 -7.82M 2.61M -7.36M -22.6M 2.03M -3.74M -8.65M
Change in inventories (cash effect) (USD) -2.7M -3.05M -1.23M -4.99M -5.2M 817,000 -2.84M 5.37M -998,000
Change in payables (cash effect) (USD) -1.52M 2.19M 6.15M 7.5M 3.94M 7.11M -5.41M 671,000 665,000
Interest paid (cash effect) (USD) — — — — — -494,000 -8.99M -8.86M -12.6M
Share-based compensation (USD) 7.01M 11.1M 13.1M 24.8M 43.3M 55.5M 62.9M 53.6M 51.5M
Operating cash flow before change in receivables (USD) -32.4M -33M 213M -152M -185M -161M -158M -91.5M -37.3M
Free cash flow (OCF - PPE - intangibles) (USD) -37.4M -38.6M 194M -168M -254M -200M -167M -98.9M -48.9M
Income detail
Research and development expense (USD) 32M 39.2M 70.7M 116M 142M 142M 122M 103M 93.8M
↳ 5y CAGR +34.7% +25.5% +7.8% -4.2%
Total comprehensive income (USD) -42.9M -46.4M -67.8M -146M -209M -203M -221M -160M -59.4M
Comprehensive income to owners (USD) -42.9M -46.4M -67.8M -146M -209M -203M -221M -160M -59.4M
Reported Feb 26, 2020 Feb 26, 2020 Feb 26, 2020 Feb 24, 2021 Feb 15, 2022 Nov 9, 2023 Feb 29, 2024 Mar 3, 2025 Feb 26, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 4, 2026 at 4:05 PM EST

Download PDF

SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended September 30, 2026.

“Adaptive achieved total company profitability ahead of expectations in Q3 and delivered 44% growth in core MRD revenue,” said Chad Robins, chief executive officer and co-founder of Adaptive Biotechnologies. “This momentum supports another increase in our full year outlook. Updated guidelines and a new definition of cure for multiple myeloma amplify the need for MRD testing and bolster clonoSEQ’s long-term potential.”

Recent Highlights

  • Achieved total company profitability in the third quarter of 2026 with adjusted EBITDA of $14.3 million and free cash flow of $7.7 million.

  • Generated revenue of $83.9 million in the third quarter of 2026. MRD revenue increased 28%, or 44% excluding milestones, versus the third quarter of 2025.

  • Delivered 39,587 clonoSEQ® tests in the third quarter of 2026, an increase of 46% versus the third quarter of 2025.

  • Submitted a technical assessment to MolDX seeking an additional Medicare bundle for maintenance testing in multiple myeloma.

  • NCCN Guidelines® established a dedicated framework for MRD assessment in multiple myeloma, including annual testing during maintenance.

  • The International Myeloma Working Group introduced the first definition of cure for multiple myeloma, requiring a five-year treatment-free period with sustained MRD negativity assessed at a sensitivity of one myeloma cell among one million cells.

  • Recognized revenue from successful data delivery under our target discovery agreement and are progressing with the Immune Medicine separation process.

  • Adaptive raised full year 2026 MRD revenue guidance to a range of $276 million to $286 million, representing annual growth of 30% to 35%.

Third Quarter 2026 Financial Results

Revenue was $83.9 million for the quarter ended September 30, 2026, representing an 11% decrease from the third quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended September 30, 2026, revenue for the current quarter increased 39% from the third quarter in the prior year. MRD revenue was $72.6 million for the quarter, representing a 28% increase from the third quarter in the prior year. Immune Medicine revenue was $11.3 million for the quarter, representing a 70% decrease from the third quarter in the prior year. Excluding revenue generated from the Genentech Agreement, Immune Medicine revenue for the quarter ended September 30, 2026 increased 229% from the third quarter in the prior year.

Operating expenses for the third quarter of 2026 were $84.4 million, compared to $83.7 million in the third quarter of the prior year, representing an increase of 1%.

Interest and other income, net was $3.8 million for the third quarter of 2026, compared to $2.2 million in the third quarter of the prior year. Interest expense was $0.5 million for the third quarter of 2026, compared to $3.0 million in the third quarter of the prior year.

Net income was $2.8 million for the third quarter of 2026, compared to $9.5 million for the same period in 2025. Excluding revenue generated from the Genentech Agreement, net loss was $24.2 million for the third quarter of 2025.

Adjusted EBITDA (non-GAAP) was $14.3 million for the third quarter of 2026, compared to $28.0 million for the third quarter of the prior year. Excluding revenue generated from the Genentech Agreement, Adjusted EBITDA was a loss of $5.8 million for the third quarter of 2025.

Cash, cash equivalents and marketable securities was $400.2 million as of September 30, 2026, inclusive of $13.8 million of cash and cash equivalents held by Digital Biotechnologies, Inc.

2026 Updated Financial Guidance

Adaptive Biotechnologies expects full year revenue for the MRD business to be between $276 million and $286 million, updated from the previous range between $268 million and $278 million. No revenue guidance is provided for the Immune Medicine business.

We expect full year total company operating expenses, including cost of revenue, to be approximately $350 million, updated from the previous range between $350 million and $355 million.

Management will provide further details on the outlook during the conference call.

Webcast and Conference Call Information

Adaptive Biotechnologies will host a conference call to discuss its third quarter 2026 financial results after market close on Wednesday, November 4, 2026 at 4:30 PM Eastern Time. The conference call can be accessed at http://investors.adaptivebiotech.com. The webcast will be archived and available for replay at least 90 days after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business segments: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer and autoimmune disorders. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward-Looking Statements

This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

Use of Non-GAAP Financial Measure

To supplement our unaudited condensed consolidated statements of operations and unaudited condensed consolidated balance sheets, which are prepared in conformity with generally accepted accounting principles in the United States of America (“GAAP”), this press release also includes references to Adjusted EBITDA, which is a non-GAAP financial measure that we define as net income (loss) attributable to Adaptive Biotechnologies Corporation adjusted for interest and other income, net, interest expense, income tax (expense) benefit, depreciation and amortization expense, impairment costs for long-lived assets, restructuring expense, share-based compensation expense and revenue interest liability extinguishment loss. We define our segment Adjusted EBITDA in the same way to the extent the net income (loss) attributable to Adaptive Biotechnologies Corporation and adjustments are allocable to each segment. We have provided reconciliations of net income (loss) attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA at the end of this press release.

Management uses Adjusted EBITDA, including segment Adjusted EBITDA, to evaluate the financial performance of our business and segments and to evaluate the effectiveness of our strategies. We present these figures because we believe they are frequently used by analysts, investors and other interested parties to evaluate companies in our industry and they facilitate comparisons on a consistent basis across reporting periods. Further, we believe it is helpful in highlighting trends in our operating results because it excludes items that are not indicative of our core operating performance.

Adjusted EBITDA, including segment Adjusted EBITDA, has limitations as an analytical tool and you should not consider it in isolation or as a substitute for analysis of our results as reported under GAAP. We may in the future incur expenses similar to the adjustments we make. In particular, we expect to incur meaningful share-based compensation expense in the future. Other limitations include that Adjusted EBITDA, including segment Adjusted EBITDA, does not reflect:

  • all expenditures or future requirements for capital expenditures or contractual commitments;

  • changes in our working capital needs;

  • interest income and interest expense, which is an ongoing element of our costs to operate;

  • income tax (expense) benefit, which may be a necessary element of our costs and ability to operate;

  • the costs of replacing the assets being depreciated and amortized, which will often have to be replaced in the future;

  • the noncash component of employee compensation expense;

  • long-lived assets impairment costs; and

  • the impact of earnings or charges resulting from matters we consider not to be reflective, on a recurring basis, of our ongoing operations, such as our restructuring activities, reductions in workforce and our revenue interest liability extinguishment loss.

In addition, Adjusted EBITDA, including segment Adjusted EBITDA, may not be comparable to similarly titled measures used by other companies in our industry or across different industries.

ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&A 201-396-1687 [email protected]

ADAPTIVE MEDIA Erica Jones, Associate Corporate Communications Director 206-279-2423 [email protected]

| Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited) | |

| | | | | | | |

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Revenue | | $ | 83,902 | | | $ | 93,973 | | | $ | 226,329 | | | $ | 205,295 | |

| Operating expenses | | | | | | | | | | | | |

| Cost of revenue | | | 19,933 | | | | 18,157 | | | | 58,806 | | | | 53,135 | |

| Research and development | | | 18,638 | | | | 23,669 | | | | 61,414 | | | | 72,006 | |

| Sales and marketing | | | 26,896 | | | | 23,470 | | | | 79,656 | | | | 70,090 | |

| General and administrative | | | 18,464 | | | | 17,959 | | | | 60,616 | | | | 53,144 | |

| Amortization of intangible assets | | | 428 | | | | 428 | | | | 1,270 | | | | 1,270 | |

| Total operating expenses | | | 84,359 | | | | 83,683 | | | | 261,762 | | | | 249,645 | |

| (Loss) income from operations | | | (457 | ) | | | 10,290 | | | | (35,433 | ) | | | (44,350 | ) |

| Interest and other income, net | | | 3,766 | | | | 2,226 | | | | 8,102 | | | | 7,296 | |

| Interest expense | | | (503 | ) | | | (2,971 | ) | | | (6,086 | ) | | | (8,824 | ) |

| Loss on revenue interest liability extinguishment | | | — | | | | — | | | | (23,733 | ) | | | — | |

| Net income (loss) | | | 2,806 | | | | 9,545 | | | | (57,150 | ) | | | (45,878 | ) |

| Add: Net loss (income) attributable to noncontrolling interests | | | 70 | | | | 1 | | | | 205 | | | | (42 | ) |

| Net income (loss) attributable to Adaptive Biotechnologies Corporation | | $ | 2,876 | | | $ | 9,546 | | | $ | (56,945 | ) | | $ | (45,920 | ) |

| Net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders, basic and diluted | | $ | 0.02 | | | $ | 0.06 | | | $ | (0.36 | ) | | $ | (0.30 | ) |

| Weighted-average shares used in computing net income (loss) per share attributable to Adaptive Biotechnologies Corporation common shareholders | | | | | | | | | | | | |

| Basic | | | 160,400,525 | | | | 152,432,307 | | | | 158,610,150 | | | | 151,248,398 | |

| Diluted | | | 186,879,656 | | | | 163,162,107 | | | | 158,610,150 | | | | 151,248,398 | |

| Adaptive Biotechnologies Condensed Consolidated Balance Sheets (in thousands, except share and per share amounts) | |

| | | | | | | |

| | | September 30, 2026 | | | December 31, 2025 | |

| | | (unaudited) | | | | |

| Assets | | | | | | |

| Current assets | | | | | | |

| Cash and cash equivalents | | $ | 75,615 | | | $ | 70,495 | |

| Short-term marketable securities (amortized cost of $223,807 and $156,246, respectively) | | | 223,339 | | | | 156,485 | |

| Accounts receivable, net | | | 66,671 | | | | 50,365 | |

| Inventory | | | 10,055 | | | | 9,820 | |

| Prepaid expenses and other current assets | | | 17,008 | | | | 13,020 | |

| Total current assets | | | 392,688 | | | | 300,185 | |

| Long-term assets | | | | | | |

| Property and equipment, net | | | 27,971 | | | | 34,107 | |

| Operating lease right-of-use assets | | | 37,990 | | | | 40,616 | |

| Long-term marketable securities (amortized cost of $102,044 and $13,220, respectively) | | | 101,227 | | | | 13,234 | |

| Restricted cash | | | 2,705 | | | | 2,689 | |

| Intangible assets, net | | | 456 | | | | 1,726 | |

| Goodwill | | | 118,972 | | | | 118,972 | |

| Other assets | | | 1,111 | | | | 1,207 | |

| Total assets | | $ | 683,120 | | | $ | 512,736 | |

| Liabilities and shareholders’ equity | | | | | | |

| Current liabilities | | | | | | |

| Accounts payable | | $ | 6,527 | | | $ | 6,467 | |

| Accrued liabilities | | | 8,201 | | | | 7,700 | |

| Accrued compensation and benefits | | | 15,107 | | | | 16,992 | |

| Current portion of operating lease liabilities | | | 9,137 | | | | 8,920 | |

| Current portion of deferred revenue | | | 59,995 | | | | 45,194 | |

| Current portion of revenue interest liability, net | | | — | | | | 4,642 | |

| Total current liabilities | | | 98,967 | | | | 89,915 | |

| Long-term liabilities | | | | | | |

| Operating lease liabilities, less current portion | | | 64,455 | | | | 70,228 | |

| Deferred revenue, less current portion | | | 408 | | | | 1,006 | |

| Revenue interest liability, net, less current portion | | | — | | | | 126,566 | |

| Convertible senior notes, net | | | 335,379 | | | | — | |

| Other long-term liabilities | | | 20 | | | | 20 | |

| Total liabilities | | | 499,229 | | | | 287,735 | |

| Commitments and contingencies | | | | | | |

| Shareholders’ equity | | | | | | |

| Preferred stock: $0.0001 par value, 10,000,000 shares authorized at September 30, 2026 and December 31, 2025; no shares issued and outstanding at September 30, 2026 and December 31, 2025 | | | — | | | | — | |

| Common stock: $0.0001 par value, 340,000,000 shares authorized at September 30, 2026 and December 31, 2025; 161,566,952 and 153,779,418 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively | | | 16 | | | | 15 | |

| Additional paid-in capital | | | 1,597,750 | | | | 1,581,848 | |

| Accumulated other comprehensive (loss) gain | | | (1,285 | ) | | | 253 | |

| Accumulated deficit | | | (1,420,268 | ) | | | (1,363,323 | ) |

| Total Adaptive Biotechnologies Corporation shareholders’ equity | | | 176,213 | | | | 218,793 | |

| Noncontrolling interests | | | 7,678 | | | | 6,208 | |

| Total shareholders’ equity | | | 183,891 | | | | 225,001 | |

| Total liabilities and shareholders’ equity | | $ | 683,120 | | | $ | 512,736 | |

| | | | | | | | | |

Adjusted EBITDA

The following is a reconciliation of net income (loss) attributable to Adaptive Biotechnologies Corporation, the most directly comparable GAAP financial measure, to Adjusted EBITDA for the periods presented (in thousands, unaudited):

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| Net income (loss) attributable to Adaptive Biotechnologies Corporation | | $ | 2,876 | | | $ | 9,546 | | | $ | (56,945 | ) | | $ | (45,920 | ) |

| Interest and other income, net | | | (3,766 | ) | | | (2,226 | ) | | | (8,102 | ) | | | (7,296 | ) |

| Interest expense | | | 503 | | | | 2,971 | | | | 6,086 | | | | 8,824 | |

| Depreciation and amortization expense | | | 3,606 | | | | 4,405 | | | | 11,138 | | | | 13,638 | |

| Impairment of long-lived assets | | | — | | | | — | | | | 347 | | | | — | |

| Restructuring expense | | | 743 | | | | — | | | | 1,463 | | | | — | |

| Share-based compensation expense | | | 10,386 | | | | 13,257 | | | | 33,433 | | | | 38,763 | |

| Loss on revenue interest liability extinguishment | | | — | | | | — | | | | 23,733 | | | | — | |

| Adjusted EBITDA | | $ | 14,348 | | | $ | 27,953 | | | $ | 11,153 | | | $ | 8,009 | |

| | | | | | | | | | | | | | | | | |

Segment Information (Including Segment Adjusted EBITDA)

The following sets forth segment information for the periods presented (in thousands, unaudited):

| | | Three Months Ended September 30, | | | Nine Months Ended September 30, | |

| | | 2026 | | | 2025 | | | 2026 | | | 2025 | |

| MRD: | | | | | | | | | | | | |

| Revenue | | $ | 72,565 | | | $ | 56,788 | | | $ | 205,826 | | | $ | 150,447 | |

| Adjusted EBITDA | | | 15,119 | | | | 6,965 | | | | 36,373 | | | | 4,766 | |

| Reconciliation of Net Income (Loss) to Adjusted EBITDA: | | | | | | | | | | | | |

| Net income (loss) | | $ | 6,483 | | | $ | (2,042 | ) | | $ | 10,227 | | | $ | (21,460 | ) |

| Depreciation and amortization expense | | | 2,475 | | | | 2,470 | | | | 7,265 | | | | 7,588 | |

| Impairment of long-lived assets | | | — | | | | — | | | | — | | | | — | |

| Restructuring expense | | | — | | | | — | | | | 325 | | | | — | |

| Share-based compensation expense | | | 6,161 | | | | 6,537 | | | | 18,556 | | | | 18,638 | |

| Adjusted EBITDA | | $ | 15,119 | | | $ | 6,965 | | | $ | 36,373 | | | $ | 4,766 | |

| | | | | | | | | | | | | |

| Immune Medicine(1): | | | | | | | | | | | | |

| Revenue | | $ | 11,337 | | | $ | 37,185 | | | $ | 20,503 | | | $ | 54,848 | |

| Adjusted EBITDA | | | 3,238 | | | | 24,111 | | | | (13,391 | ) | | | 13,284 | |

| Reconciliation of Net (Loss) Income to Adjusted EBITDA: | | | | | | | | | | | | |

| Net (loss) income | | $ | (434 | ) | | $ | 18,182 | | | $ | (26,418 | ) | | $ | (4,507 | ) |

| Depreciation and amortization expense | | | 665 | | | | 1,470 | | | | 2,496 | | | | 4,678 | |

| Impairment of long-lived assets | | | — | | | | — | | | | 347 | | | | — | |

| Restructuring expense | | | 712 | | | | — | | | | 1,107 | | | | — | |

| Share-based compensation expense | | | 2,295 | | | | 4,459 | | | | 9,077 | | | | 13,113 | |

| Adjusted EBITDA | | $ | 3,238 | | | $ | 24,111 | | | $ | (13,391 | ) | | $ | 13,284 | |

(1) Expenses related to Digital Biotechnologies, Inc. are no longer included in the Immune Medicine segment.

email

Keep up to date with Adaptive

Sign up to receive our press releases via email

Company Logo

Do Not Sell or Share My Personal Information

When you visit our Site, we store first and third-party cookies and other tracking technologies on your browser to collect information which is used to measure and analyze Site performance and usage, enhance user experiences, personalize content and ads, and provide social media and other third-party features. The California Consumer Privacy Act (CCPA) and California Privacy Rights Act (CPRA) give California residents the right to opt out of the “sale” or "sharing" of their personal information, which as defined under the CCPA and CPRA may include disclosures via certain third-party cookies and tags on our Site. You can choose to opt out of all third-party cookies on our Site, other than those that are “necessary”, by turning off the category “Sale or Sharing of Personal Information” below; however, this may impact the functionality of the Site. You can also choose to turn off only certain types of cookies, such as targeting cookies. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for our Site to function properly and cannot be switched off in our systems. Without these cookies, we cannot respond to your requests or provide you with the services you request or access on our Site. For example, we use these cookies to do the following: to remember information you have entered on forms during a web browser session; to identify you as being logged into our Site; for security purposes; and to route users to specific applications or specific servers. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the site will not function properly.

Sale and Sharing of Personal Data

Sale and Sharing of Personal Data

Under the CCPA and CPRA, California residents have the right to opt out of the “sale” and/or "sharing" of their personal information, which as defined under the law may include disclosures via certain third-party cookies and tags on our Site. Users of our Site can choose to opt out of all third-party cookies on our Site, other than those that are “necessary”, by using this toggle switch to turn off such cookies; however, this may impact the functionality of the Site. You can also choose to turn off only certain types of cookies, such as targeting cookies. Please see our Privacy Policy for more information.

  • Performance Cookies

Switch Label

These cookies collect information about how you use our Site - e.g., which pages you visit and if you experience any errors. They allow us to count visits and traffic sources so we can measure and improve the performance of our Site. For example, they help us to know which pages are the most and least popular and see how visitors move around the site. Some of our performance cookies are managed for us by third parties. If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.

  • Targeting Cookies

Switch Label

These are third-party cookies that allow us to better reach you with relevant ads and content—both on our Site and on third-party websites, apps and online services—and to measure and improve our advertising and marketing. These cookies enable third-party ad companies to track your visits to the Site, as well as other websites, apps and online services, which they use to understand your interests and activities in order to provide you more relevant ads on behalf of us and other companies. If you do not allow these cookies, you will still see ads online but they may be less relevant to you.

  • Social Media Cookies

Switch Label

These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. Similar to targeting cookies, they may enable these third-party companies to track your track your visits to the Site, as well as other websites, apps and online services, in order to understand your browsing activities and interests. Some of these third-party social media companies may make available certain privacy options to you with respect to their services and information collection; you should check their respective privacy policies for more information. If you do not allow these cookies you may not be able to use or see these sharing tools on our Site.

  • Functional Cookies

Switch Label

These cookies enable our Site to provide enhanced functionality and personalization. For example, we use these cookies to remember settings you've applied, such as language, to provide and show embedded videos and content, and to make available certain other features. Some of these cookies are managed for us by third parties, including by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

October 14, 2026 at 4:05 PM EDT

Download PDF

SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours after the event.

About Adaptive Biotechnologies

Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&A 201-396-1687 [email protected]

ADAPTIVE MEDIA Erica Jones, Associate Corporate Communications Director 206-279-2423 [email protected]

email

Keep up to date with Adaptive

Sign up to receive our press releases via email

Company Logo

Do Not Sell or Share My Personal Information

When you visit our Site, we store first and third-party cookies and other tracking technologies on your browser to collect information which is used to measure and analyze Site performance and usage, enhance user experiences, personalize content and ads, and provide social media and other third-party features. The California Consumer Privacy Act (CCPA) and California Privacy Rights Act (CPRA) give California residents the right to opt out of the “sale” or "sharing" of their personal information, which as defined under the CCPA and CPRA may include disclosures via certain third-party cookies and tags on our Site. You can choose to opt out of all third-party cookies on our Site, other than those that are “necessary”, by turning off the category “Sale or Sharing of Personal Information” below; however, this may impact the functionality of the Site. You can also choose to turn off only certain types of cookies, such as targeting cookies. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for our Site to function properly and cannot be switched off in our systems. Without these cookies, we cannot respond to your requests or provide you with the services you request or access on our Site. For example, we use these cookies to do the following: to remember information you have entered on forms during a web browser session; to identify you as being logged into our Site; for security purposes; and to route users to specific applications or specific servers. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the site will not function properly.

Sale and Sharing of Personal Data

Sale and Sharing of Personal Data

Under the CCPA and CPRA, California residents have the right to opt out of the “sale” and/or "sharing" of their personal information, which as defined under the law may include disclosures via certain third-party cookies and tags on our Site. Users of our Site can choose to opt out of all third-party cookies on our Site, other than those that are “necessary”, by using this toggle switch to turn off such cookies; however, this may impact the functionality of the Site. You can also choose to turn off only certain types of cookies, such as targeting cookies. Please see our Privacy Policy for more information.

  • Performance Cookies

Switch Label

These cookies collect information about how you use our Site - e.g., which pages you visit and if you experience any errors. They allow us to count visits and traffic sources so we can measure and improve the performance of our Site. For example, they help us to know which pages are the most and least popular and see how visitors move around the site. Some of our performance cookies are managed for us by third parties. If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.

  • Targeting Cookies

Switch Label

These are third-party cookies that allow us to better reach you with relevant ads and content—both on our Site and on third-party websites, apps and online services—and to measure and improve our advertising and marketing. These cookies enable third-party ad companies to track your visits to the Site, as well as other websites, apps and online services, which they use to understand your interests and activities in order to provide you more relevant ads on behalf of us and other companies. If you do not allow these cookies, you will still see ads online but they may be less relevant to you.

  • Social Media Cookies

Switch Label

These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. Similar to targeting cookies, they may enable these third-party companies to track your track your visits to the Site, as well as other websites, apps and online services, in order to understand your browsing activities and interests. Some of these third-party social media companies may make available certain privacy options to you with respect to their services and information collection; you should check their respective privacy policies for more information. If you do not allow these cookies you may not be able to use or see these sharing tools on our Site.

  • Functional Cookies

Switch Label

These cookies enable our Site to provide enhanced functionality and personalization. For example, we use these cookies to remember settings you've applied, such as language, to provide and show embedded videos and content, and to make available certain other features. Some of these cookies are managed for us by third parties, including by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

September 25, 2026 at 8:03 AM EDT

Download PDF

Definition requires five years off myeloma treatment with sustained MRD negativity, assessed with technology sensitive enough to identify one myeloma cell among one million cells

SEATTLE, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today highlighted the new consensus definition of cure for multiple myeloma, presented at the International Myeloma Society (IMS) 23rd Annual Meeting in Glasgow, Scotland, on behalf of IMS and the International Myeloma Working Group (IMWG).

Long considered an incurable disease, multiple myeloma is entering a new phase in which some patients are remaining free of detectable disease for years after treatment ends. Significant advances in both myeloma therapeutic strategies and disease monitoring technologies are giving clinicians more effective ways to drive deep responses and more sensitive ways to measure them. As more patients achieve these outcomes, a clear standard for determining when a long-term response may be considered a cure is necessary. The new consensus definition establishes that standard and places sustained measurable residual disease (MRD) negativity at the center of determining whether a deep response has endured over time.

Under the consensus definition reached by global myeloma experts, a patient with newly diagnosed or relapsed disease may be considered cured after five years in complete remission without any myeloma treatment. During that period, the definition requires:

  • At least four negative MRD assessments, including one at the five-year mark, with no positive result in between.

  • MRD tests must use next-generation sequencing or next-generation flow at a sensitivity of 10⁻⁶, or one myeloma cell among one million cells.

  • Advanced imaging, using PET/CT or diffusion-weighted whole-body MRI, must show no disease at the start and end of the period, with no positive scan in between if additional scans are performed.

These criteria illustrate that advanced disease assessment methodologies, including clonoSEQ®, will play a central role in determining which patients meet the definition of cure.

“In the world of treating multiple myeloma, we have now reached a point where we can actually cure patients. Part of that cure definition is that the patient has no measurable disease in their bone marrow,” said Dr. Jeffrey Wolf, clinical professor, Department of Medicine, University of California, San Francisco. “The ideal way of measuring that is to use the clonoSEQ Assay, which has been proven over many years to be the most reproducible way of defining residual disease in these patients.”

Establishing this consensus definition is the beginning of a new era for patients; significant ongoing research will be required to continue to expand the fraction who are cured and to better understand the probability of cure in specific patient subpopulations.

“Patients are excited to hear the cure conversation gain momentum but want to balance the hope with their lived reality,” said Jenny Ahlstrom, myeloma patient and CEO and founder, HealthTree Foundation. “Given that all myeloma is not the same, learning who can and will be cured will be one of the most important discoveries in the near future.”

“The consensus definition of cure in myeloma marks a defining moment for the patient community and a landmark achievement for the field. Together with last week’s NCCN Guidelines® update, this development clearly affirms that highly sensitive MRD assessment should be systematically integrated into routine myeloma care,” said Susan Bobulsky, chief commercial officer, MRD, Adaptive Biotechnologies. “As the first and only FDA-cleared next-generation sequencing MRD test, clonoSEQ is uniquely positioned to support the level of rigor the cure definition requires, giving clinicians a precise way to measure deep responses over time and offering patients clearer insight into the outcome of their treatment.”

About clonoSEQ clonoSEQ® is the first and only FDA-cleared in vitro diagnostic (IVD) test for detecting and tracking minimal (or measurable) residual disease (MRD) in patients with multiple myeloma (MM) or B-cell acute lymphoblastic leukemia (B-ALL) using bone marrow, and in patients with chronic lymphocytic leukemia (CLL) using blood or bone marrow. clonoSEQ is also available in diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and other lymphoid cancers and specimen types as a CLIA-validated laboratory-developed test (LDT). clonoSEQ is covered by Medicare for MM, CLL, ALL, DLBCL and MCL.

clonoSEQ identifies and quantifies DNA sequences in malignant cells—detecting one cancer cell in one million healthy cells—to help clinicians and researchers assess and monitor MRD with precision over time. It delivers standardized, sensitive results that inform treatment decisions, predict outcomes, and detect relapses earlier. clonoSEQ has been extensively studied in more than 300 peer-reviewed publications.

clonoSEQ is CE-marked under the EU In Vitro Diagnostic Regulation (IVDR). For intended use details in the EU, see the instructions for use, available on request.

To review the FDA-cleared uses of clonoSEQ, visit clonoSEQ.com/technical-summary.

About Adaptive Biotechnologies Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. We believe the adaptive immune system is nature’s most finely tuned diagnostic and therapeutic for most diseases, but the inability to decode it has prevented the medical community from fully leveraging its capabilities. Our proprietary immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision, and speed. We apply our platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across our two business areas: Minimal Residual Disease (MRD) and Immune Medicine. Our commercial products and clinical pipeline enable the diagnosis, monitoring, and treatment of diseases such as cancer, autoimmune disorders, and infectious diseases. Our goal is to develop and commercialize immune-driven clinical products tailored to each individual patient.

Forward-Looking Statements This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections regarding the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.

ADAPTIVE INVESTORS Karina Calzadilla, Vice President, Investor Relations and FP&A 201-396-1687 [email protected]

ADAPTIVE MEDIAErica Jones, Associate Corporate Communications Director 206-279-2423 [email protected]

Primary Logo

email

Keep up to date with Adaptive

Sign up to receive our press releases via email

Company Logo

Do Not Sell or Share My Personal Information

When you visit our Site, we store first and third-party cookies and other tracking technologies on your browser to collect information which is used to measure and analyze Site performance and usage, enhance user experiences, personalize content and ads, and provide social media and other third-party features. The California Consumer Privacy Act (CCPA) and California Privacy Rights Act (CPRA) give California residents the right to opt out of the “sale” or "sharing" of their personal information, which as defined under the CCPA and CPRA may include disclosures via certain third-party cookies and tags on our Site. You can choose to opt out of all third-party cookies on our Site, other than those that are “necessary”, by turning off the category “Sale or Sharing of Personal Information” below; however, this may impact the functionality of the Site. You can also choose to turn off only certain types of cookies, such as targeting cookies. More information

Allow All

Manage Consent Preferences

Strictly Necessary Cookies

Always Active

These cookies are necessary for our Site to function properly and cannot be switched off in our systems. Without these cookies, we cannot respond to your requests or provide you with the services you request or access on our Site. For example, we use these cookies to do the following: to remember information you have entered on forms during a web browser session; to identify you as being logged into our Site; for security purposes; and to route users to specific applications or specific servers. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the site will not function properly.

Sale and Sharing of Personal Data

Sale and Sharing of Personal Data

Under the CCPA and CPRA, California residents have the right to opt out of the “sale” and/or "sharing" of their personal information, which as defined under the law may include disclosures via certain third-party cookies and tags on our Site. Users of our Site can choose to opt out of all third-party cookies on our Site, other than those that are “necessary”, by using this toggle switch to turn off such cookies; however, this may impact the functionality of the Site. You can also choose to turn off only certain types of cookies, such as targeting cookies. Please see our Privacy Policy for more information.

  • Performance Cookies

Switch Label

These cookies collect information about how you use our Site - e.g., which pages you visit and if you experience any errors. They allow us to count visits and traffic sources so we can measure and improve the performance of our Site. For example, they help us to know which pages are the most and least popular and see how visitors move around the site. Some of our performance cookies are managed for us by third parties. If you do not allow these cookies we will not know when you have visited our site and will not be able to monitor its performance.

  • Targeting Cookies

Switch Label

These are third-party cookies that allow us to better reach you with relevant ads and content—both on our Site and on third-party websites, apps and online services—and to measure and improve our advertising and marketing. These cookies enable third-party ad companies to track your visits to the Site, as well as other websites, apps and online services, which they use to understand your interests and activities in order to provide you more relevant ads on behalf of us and other companies. If you do not allow these cookies, you will still see ads online but they may be less relevant to you.

  • Social Media Cookies

Switch Label

These cookies are set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. Similar to targeting cookies, they may enable these third-party companies to track your track your visits to the Site, as well as other websites, apps and online services, in order to understand your browsing activities and interests. Some of these third-party social media companies may make available certain privacy options to you with respect to their services and information collection; you should check their respective privacy policies for more information. If you do not allow these cookies you may not be able to use or see these sharing tools on our Site.

  • Functional Cookies

Switch Label

These cookies enable our Site to provide enhanced functionality and personalization. For example, we use these cookies to remember settings you've applied, such as language, to provide and show embedded videos and content, and to make available certain other features. Some of these cookies are managed for us by third parties, including by third party providers whose services we have added to our pages. If you do not allow these cookies then some or all of these services may not function properly.

Cookie List

Clear

checkbox label label

Apply Cancel

Leg.Interest

checkbox label label

checkbox label label

checkbox label label

Powered by Onetrust

Prompts

Adaptive Biotechnologies Corporation (ticker ADPT), listed in United States.

Company History

Date Change Detail
Jun 21, 2012 Renamed Adaptive TCR Corp → ADAPTIVE BIOTECHNOLOGIES CORP

ETFs Holding Adaptive Biotechnologies Corporation

ETF Weight in ETF Shares Market value As of
HELX 3.99% 51,956 $ 1.114M Jun 30, 2026
ARKG 3.09% 1,974,865 $ 56.264M Nov 18, 2026
MEDI 0.50% 7,323 $ 215.882K Nov 12, 2026
MMSC 0.50% 9,039 $ 251.917K Nov 16, 2026
TMED 0.42% 4,479 $ 96.075K Jun 30, 2026
OASC 0.39% 14,778 $ 368.268K Aug 31, 2026
AFSM 0.29% 15,292 $ 426.188K Nov 16, 2026
FSEG 0.27% 728 $ 15.616K Jun 30, 2026
FESM 0.24% 641,984 $ 13.771M Jun 30, 2026
ESSC 0.24% 3,763 $ 84.931K Jul 31, 2026
SCDS 0.22% 719 $ 20.484K Nov 17, 2026
MSSM 0.21% 61,165 $ 1.524M Aug 31, 2026
PSC 0.18% 194,092 $ 4.163M Jun 30, 2026
RESM 0.15% 264 $ 5,662.80 Jun 30, 2026
FSML 0.10% 6,038 $ 129.515K Jun 30, 2026
VFMO 0.08% 59,751 $ 1.489M Aug 31, 2026
FEAC 0.00% 8 $ 171.60 Jun 30, 2026
AVSU 0.00% 15 $ 418.05 Nov 16, 2026